A major pharmaceutical company in the U.S. Is making it easier for diabetics to access affordable insulin —
Announcing a 70 percent price reduction to its most commonly prescribed insulins and expanding it’s program that caps out-of-pocket expenses for patients at 35 dollars a month.
The federal government — as recent as president biden’s state of the union address — has been putting pressure on big pharma — to lower drug costs for americans.
{“Big pharma has been unfairly charging people hundreds of dollars 400-500 dollars a month making record profits, not anymore. Cheers. Not anymore.”}
There has been a bipartisan effort among congress and the states to improve affordability for the life-saving medication used by millions of americans.
Eli lilly — a major provider of insulin — has been on board.
Announcing today its non-branded insulin vial will be reduced to 25 dollars a vial — starting may first.
It will be the lowest list-priced mealtime insulin available.
Some of its most popular branded insulins will also be reduced by
[l3: popular insulin prices cut up to 78%]
Up to 78 percent in the fourth quarter of this year.
Eli lilly has been progressively working to lower insulin drug costs for years.
They lowered its most popular non-branded insulin by 50 percent in 20-19.
And in 2020 introduced its lilly insulin value program…Which gave uninsured and commercially insured diabetics access to insulin for 35 dollars a month through a partnered retail pharmacy.
Today — they’re expanding that program —
Introducing an easy-to-download savings card that can be used by insured or uninsured diabetics and can be used at 85% of all pharmacies.
There’s been a $35 a month federal price cap for medicare patients.
But this program opens the savings up to anybody.